Expert Interview
Discussing the current standard of care and the potential of VLA15, a multivalent recombinant protein vaccine candidate that targets six serotypes of Borrelia currently in development by Valneva and Pfizer.
Ticker(s): VALN, PFEInstitution: Univ of Pennsylvania.
- Associate Professor of Clinical Medicine at the Perelman School of
Medicine at the University of Pennsylvania. - Concentration is ambulatory Infectious Diseases where she has a robust HIV practice and is a regional expert in tick borne diseases.
- Served as the Medical Director of Penn Community ID Practice, Penn Home Infusion and Penn Care at Home.
- Currentlv she is the Medical Director of the Outpatient Parenteral Antimicrobial Therapy (OPAT) Program at Penn Presbyterian Medical Center.
- Chaired the IDSA 2019 OPAT Guideline and co-edited the 2016 IDSA OPAT Handbook. She
- An Epic physician builder and serves as the ID division Epic champion.
- Served as the principle ambulatory preceptor for over 15 Infectious Diseases fellows at Penn since 1999 and won the Infectious Diseases Division Faculty Teaching award in 2021.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
